Health resource consumption and costs attributable to chemotherapy-induced toxicity in german routine hospital care in lymphoproliferative disorder and NSCLC patients

Annals of Oncology

Volumn 22, Issue 10, 2011, Pages 2310-2319

  Paessens, B J ^a   von Schilling, C ^b,c   Berger, K ^d   Shlaen, M ^e   Muller Thomas C ^b   Bernard, R ^a   Peschel, C ^b   Ihbe Heffinger, A ^a,b  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c Klinikum Freising   (Germany)

^d LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^e IQVIA   (United States)

Author keywords

Combined antineoplastic treatment protocols adverse effects; Costs and cost analysis; Health resources; Neoplasms drug therapy

Indexed keywords

ANTIBIOTIC AGENT; ANTIEMETIC AGENT; ANTIFUNGAL AGENT; ANTINEOPLASTIC AGENT; COLONY STIMULATING FACTOR; CYCLOPHOSPHAMIDE; DOXORUBICIN; GLUCOCORTICOID; PREDNISONE; VINCRISTINE;

ADULT; AGED; ALLERGIC REACTION; ANEMIA; ARTICLE; ASTHENIA; BLEEDING; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CHRONIC LYMPHATIC LEUKEMIA; COHORT ANALYSIS; COMORBIDITY; CONSTIPATION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DIARRHEA; DISEASE ASSOCIATION; DRUG FEVER; DRUG INDUCED DISEASE; DYSPNEA; EDEMA; FATIGUE; FEMALE; GERMANY; HEALTH CARE COST; HEALTH CARE UTILIZATION; HODGKIN DISEASE; HOSPITAL CARE; HUMAN; ILEUS; INFECTION; INTENSIVE CARE; LENGTH OF STAY; LETHARGY; LEUKOPENIA; LONGITUDINAL STUDY; LUNG EMBOLISM; LUNG NON SMALL CELL CANCER; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL PRACTICE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; NONHODGKIN LYMPHOMA; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PHLEBITIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; THROMBOSIS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; COHORT STUDIES; FEMALE; GERMANY; HEALTH CARE COSTS; HEALTH RESOURCES; HUMANS; LONGITUDINAL STUDIES; LUNG NEOPLASMS; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 79957473238     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq759     Document Type: Article

References (40)

1. Feyer P, Kleeberg U, Steingräber M et al. Frequency of side effects in outpatient cancer care and their influence on patient satisfaction-a prospective survey using the PASQOC® questionnaire. Support Care Cancer 2008; 16: 567-575.
2. Ihbe-Heffinger A, Ehlken B, Bernard R et al. The impact of delayed chemotherapy-induced nausea and vomiting on patients, health resource utilization and costs in German cancer centers. Ann Oncol 2004; 15: 526-536.
3. Ludwig H, Van Belle S, Barrett-Lee P et al. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 2004; 40: 2293-2306.
4. Wolff D, Culakova E, Poniewierski MS et al. Predictors of chemotherapy-induced neutropenia and its complications: results from a prospective nationwide registry. J Support Oncol 2005; 3: 24-25.
5. Braun M, Jacobs VR, Wagenpfeil S et al. Cost analysis comparing an anthracycline/docetaxel regimen to CMF in patients with early stage breast cancer. Onkologie 2009; 32: 473-481.
6. Lyman GH, Dale DC, Friedberg J et al. Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study. J Clin Oncol 2004; 22: 4302-4311.
7. Kuderer NM, Dale DC, Crawford J et al. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 2006; 106: 2258-2266.
8. Lau PM, Stewart K, Dooley M. The ten most common adverse drug reactions (ADRs) in oncology patients: do they matter to you? Support Care Cancer 2004; 12: 626-633.
9. Elting L, Shih Y-C. The economic burden of supportive care of cancer patients. Support Care Cancer 2004; 12: 219-226.
10. Liou S. Economic burden of haematological adverse effects in cancer patients: a systematic review. Clin Drug Investig 2007; 27: 381-396.
11. Mayordomo JI, Lopez A, Vinolas N et al. Retrospective cost analysis of management of febrile neutropenia in cancer patients in Spain. Curr Med Res Opin 2009; 25: 2533-2542.
12. Herold M, Hieke K. Costs of toxicity during chemotherapy with CHOP, COP/CVP, and fludarabine. Eur J Health Econ 2002; 3: 166-172.
13. Lyman GH, Berndt ER, Kallich JD et al. The economic burden of anemia in cancer patients receiving chemotherapy. Value Health 2005; 8: 149-156.
14. Bennett CL, Calhoun EA. Evaluating the total costs of chemotherapy-induced febrile neutropenia: results from a pilot study with community oncology cancer patients. Oncologist 2007; 12: 478-483.
15. Weycker D, Malin J, Edelsberg J et al. Cost of neutropenic complications of chemotherapy. Ann Oncol 2008; 19: 454-460.
16. Elting LS, Cantor SB, Martin CG et al. Cost of chemotherapy-induced thrombocytopenia among patients with lymphoma or solid tumors. Cancer 2003; 97: 1541-1550.
17. Elting LS, Rubenstein EB, Martin CG et al. Incidence, cost, and outcomes of bleeding and chemotherapy dose modification among solid tumor patients with chemotherapy-induced thrombocytopenia. J Clin Oncol 2001; 19: 1137-1146.
18. Elting LS, Cooksley C, Chambers M et al. The burdens of cancer therapy. Clinical and economic outcomes of chemotherapy-induced mucositis. Cancer 2003; 98: 1531-1539.
19. Annemans L, Strens D, Lox E et al. Cost-effectiveness analysis of aprepitant in the prevention of chemotherapy-induced nausea and vomiting in Belgium. Support Care Cancer 2008; 16: 905-915.
20. Jacobs VR, Thoedtmann J, Euler U et al. Physician-based active cost management of oncological therapies reducing pharmaceutical costs by 83.4% in two years without leaving standard of care. Onkologie 2005; 28: 441-445.
21. Ziepert M, Schmits R, Trumper L et al. Prognostic factors for hematotoxicity of chemotherapy in aggressive non-Hodgkin's lymphoma. Ann Oncol 2008; 19: 752-762.
22. Azzoli CG, Baker S Jr, Temin S et al. American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 2009; 27: 6251-6266.
23. NCCN. Clinical Practice Guidelines in Oncology™: Non-Hodgkin's Lymphomas. 2009: http://www.nccn.org/professionals/physician_gls/PDF/nhl.pdf (3 December 2009, date last accessed).
24. The Uppsala Monitoring Centre. The use of the WHO-UMC system for standardised case causality assessment. 2007: http/www.who-umc.org/graphics/4409.pdf (3 December 2009, date last accessed).
25. Graf von der Schulenburg JM, Greiner W, Jost F et al. German recommendations on health economic evaluation: third and updated version of the Hanover Consensus. Value Health 2008; 11: 539-544.
26. Schoffski O, Breitscheidel L, Benter U et al. Resource utilisation and costs in patients with type 2 diabetes mellitus treated with insulin glargine or conventional basal insulin under real-world conditions in Germany: LIVE-SPP study. J Med Econ 2008; 11: 695-712.
27. Spindler J, Schelhase T. Krankenhauslandschaft im Umbruch. 2009; http://www.destatis.de/jetspeed/portal/cms/Sites/destatis/Internet/DE/Content/Publikationen/Querschnittsveroeffentlichungen/WirtschaftStatistik/Monatsausgaben/WistaJuli09,property=file.pdf (3 December 2009, date last accessed).
28. Elting LS, Cooksley C, Bekele BN et al. Generalizability of cancer clinical trial results: prognostic differences between participants and nonparticipants. Cancer 2006; 106: 2452-2458.
29. Tjan-Heijnen VC, Caleo S, Postmus PE et al. Economic evaluation of antibiotic prophylaxis in small-cell lung cancer patients receiving chemotherapy: an EORTC double-blind placebo-controlled phase III study (08923). Ann Oncol 2003; 14: 248-257.
30. Ihbe-Heffinger A, Paessens BJ, von Schilling C et al. Costs associated with routine management of febrile neutropenia in three tumor types in Germany. Support Care Cancer 2009; 17: 921.
31. Liu Z, Doan QV, Malin J, Leonard R. The economic value of primary prophylaxis using pegfilgrastim compared with filgrastim in patients with breast cancer in the UK. Appl Health Econ Health Policy 2009; 7: 193-205.
32. Sehouli J, Goertz A, Steinle T et al. [Pegfilgrastim vs filgrastim in primary prophylaxis of febrile neutropenia in patients with breast cancer after chemotherapy: a cost-effectiveness analysis for Germany]. Dtsch Med Wochenschr 2010; 135: 385-389.
33. Lyman GH, Lalla A, Barron RL, Dubois RW. Cost-effectiveness of pegfilgrastim versus filgrastim primary prophylaxis in women with early-stage breast cancer receiving chemotherapy in the United States. Clin Ther 2009; 31: 1092-1104.
34. Klastersky J, Paesmans M, Rubenstein EB et al. The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 2000; 18: 3038-3051.
35. Lalami Y, Paesmans M, Muanza F et al. Can we predict the duration of chemotherapy-induced neutropenia in febrile neutropenic patients, focusing on regimen-specific risk factors? A retrospective analysis. Ann Oncol 2006; 17: 507-514.
36. Mandrekar SJ, Northfelt DW, Schild SE et al. Impact of pretreatment factors on adverse events: a pooled analysis of North Central Cancer Treatment Group advanced stage non-small cell lung cancer trials. J Thorac Oncol 2006; 1: 556-563.
37. Marcuello E, Altes A, Menoyo A et al. UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer. Br J Cancer 2004; 91: 678-682.
38. Gross E, Busse B, Riemenschneider M et al. Strong association of a common dihydropyrimidine dehydrogenase gene polymorphism with fluoropyrimidine-related toxicity in cancer patients. PLoS One 2008; 3: e4003.
39. Aprile G, Ramoni M, Keefe D, Sonis S. Network analyses to define chemotherapy toxicity clusters in patients with colorectal cancer (CRC). J Clin Oncol 2007; 25(Suppl 18): 9045.
40. Aprile G, Ramoni M, Keefe D, Sonis S. Links between regimen-related toxicities in patients being treated for colorectal cancer. Curr Opin Support Palliat Care 2009; 3: 50-54.